Arterial hypertension assessment in a population with chronic myeloid leukemia

Abstract Treatment of chronic myeloid leukaemia (CML) is based on tyrosine kinase inhibitors (TKI), whose introduction in 2001 improved the survival rate after 5 years from 40 to 90%. The longevity increase has been accompanied by a higher incidence of cardiovascular events (CVE) that can be explain...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ricardo Roa-Chamorro, Fernando Jaén-Águila, José Manuel Puerta-Puerta, Lucía Torres-Quintero, Pablo González-Bustos, Juan Diego Mediavilla-García
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/f027b0237aed45dd809a0b10112f4dd8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f027b0237aed45dd809a0b10112f4dd8
record_format	dspace
spelling	oai:doaj.org-article:f027b0237aed45dd809a0b10112f4dd82021-12-02T16:26:30ZArterial hypertension assessment in a population with chronic myeloid leukemia10.1038/s41598-021-94127-22045-2322https://doaj.org/article/f027b0237aed45dd809a0b10112f4dd82021-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-94127-2https://doaj.org/toc/2045-2322Abstract Treatment of chronic myeloid leukaemia (CML) is based on tyrosine kinase inhibitors (TKI), whose introduction in 2001 improved the survival rate after 5 years from 40 to 90%. The longevity increase has been accompanied by a higher incidence of cardiovascular events (CVE) that can be explained due to the sum of cardiovascular risk factors (CVRF) together with the secondary effects of the TKI. The effect of the TKI over the blood pressure control is still unknown. An observational cross-sectional study of patients with CML under treatment with TKI (imatinib, dasatinib and nilotinib) was conducted. Blood pressure was analyzed through sphygmomanometer and 24-h ambulatory blood pressure monitoring (ABPM). A total of 73 patients were included, 57 treated with a single line of treatment. 32.9% of the total of individuals under this study showed uncontrolled blood pressure according to the ABPM. The factors related to uncontrolled BP were overweight, dyslipidemia, alcohol use, pulse wave velocity a high/very high cardiovascular risk. The subjects who received treatment with nilotinib did present worse control of their blood pressure in ABPM than those treated with imatinib and dasatinib (p = 0.041). This finding could indicate that an uncontrolled blood pressure is implied in the pro-inflammatory and pro-atherogenic mechanism underlying the development of the cardiovascular disease in those patients under treatment with nilotinib. The ABPM is a useful tool in the diagnosis and treatment of HT, being the reason why it should be included in the assessment of patients with CML whose HT diagnosis proves uncertain.Ricardo Roa-ChamorroFernando Jaén-ÁguilaJosé Manuel Puerta-PuertaLucía Torres-QuinteroPablo González-BustosJuan Diego Mediavilla-GarcíaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Ricardo Roa-Chamorro Fernando Jaén-Águila José Manuel Puerta-Puerta Lucía Torres-Quintero Pablo González-Bustos Juan Diego Mediavilla-García Arterial hypertension assessment in a population with chronic myeloid leukemia
description	Abstract Treatment of chronic myeloid leukaemia (CML) is based on tyrosine kinase inhibitors (TKI), whose introduction in 2001 improved the survival rate after 5 years from 40 to 90%. The longevity increase has been accompanied by a higher incidence of cardiovascular events (CVE) that can be explained due to the sum of cardiovascular risk factors (CVRF) together with the secondary effects of the TKI. The effect of the TKI over the blood pressure control is still unknown. An observational cross-sectional study of patients with CML under treatment with TKI (imatinib, dasatinib and nilotinib) was conducted. Blood pressure was analyzed through sphygmomanometer and 24-h ambulatory blood pressure monitoring (ABPM). A total of 73 patients were included, 57 treated with a single line of treatment. 32.9% of the total of individuals under this study showed uncontrolled blood pressure according to the ABPM. The factors related to uncontrolled BP were overweight, dyslipidemia, alcohol use, pulse wave velocity a high/very high cardiovascular risk. The subjects who received treatment with nilotinib did present worse control of their blood pressure in ABPM than those treated with imatinib and dasatinib (p = 0.041). This finding could indicate that an uncontrolled blood pressure is implied in the pro-inflammatory and pro-atherogenic mechanism underlying the development of the cardiovascular disease in those patients under treatment with nilotinib. The ABPM is a useful tool in the diagnosis and treatment of HT, being the reason why it should be included in the assessment of patients with CML whose HT diagnosis proves uncertain.
format	article
author	Ricardo Roa-Chamorro Fernando Jaén-Águila José Manuel Puerta-Puerta Lucía Torres-Quintero Pablo González-Bustos Juan Diego Mediavilla-García
author_facet	Ricardo Roa-Chamorro Fernando Jaén-Águila José Manuel Puerta-Puerta Lucía Torres-Quintero Pablo González-Bustos Juan Diego Mediavilla-García
author_sort	Ricardo Roa-Chamorro
title	Arterial hypertension assessment in a population with chronic myeloid leukemia
title_short	Arterial hypertension assessment in a population with chronic myeloid leukemia
title_full	Arterial hypertension assessment in a population with chronic myeloid leukemia
title_fullStr	Arterial hypertension assessment in a population with chronic myeloid leukemia
title_full_unstemmed	Arterial hypertension assessment in a population with chronic myeloid leukemia
title_sort	arterial hypertension assessment in a population with chronic myeloid leukemia
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/f027b0237aed45dd809a0b10112f4dd8
work_keys_str_mv	AT ricardoroachamorro arterialhypertensionassessmentinapopulationwithchronicmyeloidleukemia AT fernandojaenaguila arterialhypertensionassessmentinapopulationwithchronicmyeloidleukemia AT josemanuelpuertapuerta arterialhypertensionassessmentinapopulationwithchronicmyeloidleukemia AT luciatorresquintero arterialhypertensionassessmentinapopulationwithchronicmyeloidleukemia AT pablogonzalezbustos arterialhypertensionassessmentinapopulationwithchronicmyeloidleukemia AT juandiegomediavillagarcia arterialhypertensionassessmentinapopulationwithchronicmyeloidleukemia
_version_	1718384089918078976

Arterial hypertension assessment in a population with chronic myeloid leukemia

Ejemplares similares